J. Bourdon, p53 and its isoforms in cancer, British Journal of Cancer, vol.20, issue.3, pp.277-82, 2007.
DOI : 10.1038/35003607
URL : https://hal.archives-ouvertes.fr/inserm-00409543

J. Chen, S. Ng, C. Chang, Z. Zhang, J. Bourdon et al., p53 isoform ??113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish, Genes & Development, vol.23, issue.3, pp.278-90, 2009.
DOI : 10.1101/gad.1761609
URL : https://hal.archives-ouvertes.fr/inserm-00409849

M. Aoubala, F. Murray-zmijewski, M. Khoury, K. Fernandes, S. Perrier et al., p53 directly transactivates ??133p53??, regulating cell fate outcome in response to DNA damage, Cell Death and Differentiation, vol.101, issue.2, pp.248-58, 2011.
DOI : 10.1016/0027-5107(93)90162-9
URL : https://hal.archives-ouvertes.fr/inserm-00840976

K. Fujita, A. Mondal, I. Horikawa, G. Nguyen, K. Kumamoto et al., p53 isoforms ??133p53 and p53?? are endogenous regulators of replicative cellular senescence, Nature Cell Biology, vol.11, issue.9, pp.1135-1177, 2009.
DOI : 10.1001/jama.299.4.425

J. Teodoro, S. Evans, and M. Green, Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome, Journal of Molecular Medicine, vol.289, issue.11, pp.1175-86, 2007.
DOI : 10.1007/s00109-007-0221-2

P. Fraisl, M. Mazzone, T. Schmidt, and P. Carmeliet, Regulation of Angiogenesis by Oxygen and Metabolism, Developmental Cell, vol.16, issue.2, pp.167-79, 2009.
DOI : 10.1016/j.devcel.2009.01.003

J. Pouyssegur, F. Dayan, and N. Mazure, Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature, vol.9, issue.7092, pp.437-480, 2006.
DOI : 10.1038/nature04871
URL : https://hal.archives-ouvertes.fr/hal-00321054

K. Dameron, O. Volpert, M. Tainsky, and N. Bouck, Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1, Science, vol.265, issue.5178, pp.1582-1586, 1994.
DOI : 10.1126/science.7521539

J. Folkman, B. Galy, L. Creancier, C. Zanibellato, A. Prats et al., Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma, Sci STKE. Oncogene. Cancer Res, vol.20, issue.1218, pp.35-111669, 2001.

T. Ueba, T. Nosaka, J. Takahashi, F. Shibata, R. Florkiewicz et al., Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells., Proceedings of the National Academy of Sciences, vol.91, issue.19, pp.9009-9022, 1994.
DOI : 10.1073/pnas.91.19.9009

S. Giuriato, S. Ryeom, A. Fan, P. Bachireddy, R. Lynch et al., Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch, ProcNatlAcadSci U S A. Naumov GN Cell Cycle, vol.1035, issue.1616, pp.16266-711779, 2006.

M. Wong, A. Prawira, A. Kaye, and C. Hovens, Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas, Journal of Clinical Neuroscience, vol.16, issue.9, pp.1119-1149, 2009.
DOI : 10.1016/j.jocn.2009.02.009

V. Marcel, V. Vijayakumar, L. Fernandez-cuesta, H. Hafsi, C. Sagne et al., p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene. 2010. 19

M. Khoury and J. Bourdon, p53 Isoforms: An Intracellular Microprocessor? Genes Cancer, pp.453-65, 2011.
DOI : 10.1177/1947601911408893
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135639

J. Bourdon, M. Khoury, A. Diot, L. Baker, K. Fernandes et al., p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients):R7. 22 Differential regulation of p53 function by the N-terminal DeltaNp53 and Delta113p53 isoforms in zebrafish embryos, Breast Cancer Res. BMC Dev Biol, vol.13110, pp.102-125, 2010.

H. Ohgaki and P. Kleihues, Genetic Pathways to Primary and Secondary Glioblastoma, The American Journal of Pathology, vol.170, issue.5, pp.1445-53, 2007.
DOI : 10.2353/ajpath.2007.070011
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1854940

A. Sirven, E. Ravet, P. Charneau, V. Zennou, L. Coulombel et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors, Cancer Cell. MolTher, vol.153, issue.274, pp.220-31438, 2001.

M. Jensen, J. Jorgensen, T. Binderup, and A. Kjaer, Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper, Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide, pp.7507-1216, 2004.
DOI : 10.1016/j.acra.2005.03.062